Stepan Company Earnings Call Signals Cost-Focused Pivot

Stepan Company ((SCL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Stepan Company’s latest earnings call struck a cautiously optimistic tone as management highlighted solid full-year EBITDA growth, stronger cash generation, and a healthier balance sheet, even as near-term profitability remains pressured. Executives framed 2025 as a transition year, with cost inflation, weaker Surfactants demand, and macro uncertainty weighing on results but paving the way for a stronger 2026.

Full-Year Profitability Improves Despite Mixed Bottom Line

Adjusted EBITDA for fiscal 2025 rose 6% year over year to $199 million, with total EBITDA up 11% to $208 million, supported by disciplined pricing, cost controls, and favorable mix. However, adjusted net income declined to $41.7 million as weaker Surfactants operating income, lower capitalized interest, and a higher tax rate offset operating gains.

Cash Generation Strengthens and Leverage Moves Lower

Stepan generated $25.4 million of free cash flow for the year, a sharp improvement from the prior year’s negative Q4 contribution. Cash from operations reached $148 million, allowing net debt to fall to $494 million and net leverage to improve from 2.8 times to roughly 2.5 times, giving the company more flexibility in a volatile environment.

Organic Volume Growth Led by Polymers

Global organic sales volume grew 2% for the full year, driven largely by robust demand in Polymers. In the fourth quarter, Polymers volume rose 11%, pushing net sales to $132 million from $113 million and lifting adjusted EBITDA by about 9%, even as pricing and competition pressured unit margins.

Pasadena Facility Commissioned and Ramping

The company successfully commissioned its new Pasadena alkoxylation facility, which is now in the production ramp phase. Management expects utilization to reach roughly 70% to 80% in 2026 and achieve full utilization in 2027, positioning the site as a cornerstone for footprint optimization and future growth.

Project Catalyst Targets $100 Million in Savings

Stepan unveiled Project Catalyst, an aggressive cost-savings initiative aimed at delivering about $100 million in pretax savings over two years. Around 60% of those savings, or roughly $60 million, are expected in 2026, with efforts centered on footprint rationalization, operational efficiency, and organizational streamlining to offset fixed-cost inflation.

Steady Dividend Growth Supports Shareholder Returns

The board approved a quarterly dividend of $0.395 per share payable in March 2026, a 2.6% increase from the prior year level. This marks the 58th consecutive annual dividend increase, with Stepan paying $8.9 million in dividends during 2025 as it balances shareholder returns with investment in strategic projects.

Record Safety Performance Underpins Operations

Management highlighted the best safety performance in the company’s history as a notable milestone in 2025. The improvement signals more than just compliance, as a stronger safety culture typically supports higher reliability, fewer disruptions, and potentially lower operating costs over time.

Selective Growth in Targeted End Markets

Growth was concentrated in strategic niches such as crop productivity, oilfield applications with tier two and three customers, global Polymers, and Specialty Products. Medium chain triglycerides delivered double-digit volume gains, while tier two and three customer segments posted mid-single-digit growth, demonstrating Stepan’s pivot toward higher-value markets.

Fourth-Quarter EBITDA Dips on Surfactants Weakness

Consolidated adjusted EBITDA for Q4 2025 slipped about 3% to $33.8 million from $35 million a year ago. The decline was driven primarily by weaker Surfactants performance and elevated raw material costs, which outweighed the volume and earnings gains reported in Polymers.

Surfactants Suffer from Volume and Margin Pressure

Surfactants organic volume fell 3% in the fourth quarter, reflecting softer demand in commodity consumer and construction markets. Although net sales increased to $402 million from $379 million on pricing, mix, and foreign exchange, sharply higher oleochemical input costs compressed margins and weighed on segment EBITDA.

Oleochemical Inflation Weighs on Margins, Recovery Skewed to H2 2026

Significant inflation in coconut oil and related oleochemical feedstocks during the second half of 2025 created a lagged margin squeeze due to long supply chains. Management expects the worst of the pressure to pass and believes margin recovery will become more visible in the second half of 2026 as lower-cost inventory flows through.

Weather-Related Headwind Adds to Near-Term Earnings Pressure

A historic winter in the first quarter of 2026 is expected to cut EBITDA by around $6 million, with most of the impact hitting the Surfactants segment. The company anticipates recovering at least half of that lost earnings across the remaining quarters of the year as operations normalize and demand rebounds.

Footprint Rationalization and Site Closures Underway

As part of Project Catalyst, Stepan is closing its Fieldsboro, N.J. facility and decommissioning selected assets at Millsdale and Stalybridge to reduce commodity Surfactants capacity. These moves should lower fixed costs and sharpen strategic focus but come with restructuring charges and tangible impacts on employees and local communities.

Polymers Margins Face Competitive and Pricing Pressure

Despite strong volume growth, Polymers unit margins came under pressure in Q4 as lower raw material costs were passed through to customers and competitive intensity increased. The resulting price compression partially offset the volume-driven EBITDA gains, underscoring the need for continued discipline in mix, innovation, and cost structure.

Tariffs and Macro Volatility Remain Key Risk Factors

Management flagged tariffs and broader macroeconomic uncertainty as ongoing headwinds for 2026, citing potential pressure on supply chain competitiveness and input costs. These external risks add another layer of complexity to execution of Project Catalyst and the Pasadena ramp, and they could sway profitability if conditions worsen.

Guidance Emphasizes Cost Savings, Pasadena Ramp, and Cash Discipline

Looking ahead, Stepan’s guidance centers on extracting about $100 million of pretax savings from Project Catalyst over two years, with roughly $60 million expected to land in 2026 against a roughly $750 million fixed-cost base facing more than 3% inflation. Management is targeting adjusted EBITDA growth in 2026 versus the 2025 baseline of $199 million, continued positive free cash flow, capital spending of $105 million to $115 million, and a sustained ramp of Pasadena toward full utilization by 2027 while absorbing a weather-driven EBITDA hit in early 2026.

Stepan’s earnings call painted the picture of a company in the midst of a strategic reset, leveraging new capacity and cost actions to offset cyclical and input-cost headwinds. Investors will be watching closely to see if Project Catalyst, structural footprint changes, and a recovering Surfactants margin profile can translate into the stronger second-half 2026 performance management is targeting.